You're moving
Women on CJC-1295/Ipamorelin protocols consistently report improved daytime energy and a reduction in the cognitive fog that often appears during perimenopause
Research shows that patients who follow structured treatment plans achieve better outcomes than those who do not
From the approval of Orlistat (Xenical) in 1999, which focused on reducing dietary fat absorption, to the emergence of highly effective incretin-based therapies such as liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound), we have witnessed a fundamental shift in how obesity is understood and treated
Millions of people today deal with ongoing joint aches, stiffness, swelling, and unexplained fatigue linked to low-grade inflammation
In March, FDA approved the first ever treatment for Prader-Willi syndrome